REG-ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it’s At the Market (ATM) offering agreement with H.C. Wainwright & Co.

Following the reported sale of these ADSs, Addex’s cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares.